Holen Sie sich die Stockscreener-App
2.00
9.09%
-0.20
Handel nachbörslich:
2.03
0.03
+1.50%
Schlusskurs vom Vortag:
$2.20
Offen:
$2.29
24-Stunden-Volumen:
46,025
Relative Volume:
0.63
Marktkapitalisierung:
$30.18M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.61M
KGV:
-1.5449
EPS:
-1.2946
Netto-Cashflow:
$-11.82M
1W Leistung:
-13.79%
1M Leistung:
-27.27%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.98
$2.29
1-Wochen-Bereich:
$1.98
$2.40
52-Wochen-Spanne:
$1.98
$4.965
Grace Therapeutics Inc Stock (GRCE) Company Profile
Firmenname
Grace Therapeutics Inc
Sektor
Branche
Telefon
609-322-1602
Adresse
103 CARNEGIE CENTER, PRINCETON
Vergleichen Sie GRCE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GRCE
Grace Therapeutics Inc
|
2.00 | 30.18M | 0 | -11.61M | -11.82M | -1.2946 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Grace Therapeutics Inc Stock (GRCE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-09-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-07-06 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2020-01-13 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2019-08-29 | Eingeleitet | B. Riley FBR | Buy |
| 2019-07-18 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-26 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Grace Therapeutics Inc Aktie (GRCE) Neueste Nachrichten
Acasti Pharma stock plunges to 52-week low at $2.02 By Investing.com - Investing.com UK
Aneurysmal Subarachnoid Hemorrhage Market to Reach New Heights - openPR.com
Aneurysmal Subarachnoid Hemorrhage Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Acasti Pharma Inc., BIT Pharma, Aaron Cook, Haaglanden Medical Centre - Barchart.com
February’s phase III wins include Qyuns’ ankylosing spondylitis data - BioWorld MedTech
Grace Therapeutics secures up to $30 million financing - MSN
ASUS Introduces Ascent GX10 AI Supercomputer Powered by NVIDIA GB10 Grace Blackwell Superchip - Yahoo Finance
Cadence Accelerates AI-Driven Engineering Design and Science with NVIDIA Grace Blackwell - Yahoo Finance
Subarachnoid Hemorrhage Treatment Market Size in the 7MM - openPR
Acasti Pharma stock hits 52-week low at $2.12 amid challenges - Investing.com Australia
Acasti Pharma stock hits 52-week low at $2.12 amid challenges By Investing.com - Investing.com South Africa
Tesla’s fall from grace may have no equal, says JPMorgan: ‘We struggle to think of anything analogous’ - Yahoo Finance
The Inner Circle acknowledges, Grace Merrell Slezak as a Pinnacle Professional Member Inner Circle of Excellence - Yahoo Finance
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem - Yahoo Finance
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors - The Manila Times
Grace Therapeutics Reports Q3 Progress and Financial Results - TipRanks
Grace Therapeutics Files Form S-3 for Flexible Securities Offering - TipRanks
Grace Therapeutics to offer up to 8.8 mln shares by selling stockholders, SEC Filing shows - Marketscreener.com
Moderna, Inc. - Britannica
CORTCorcept Therapeutics Inc Latest Stock News & Market Updates - StockTitan
New Biotech Stocks at Investorideas.com - Investorideas.com newswire
CORCEPT THERAPEUTICS INC SEC 10-K Report - TradingView
Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - The Manila Times
Can Grace Therapeutics' Novel aSAH Treatment Impress Investors at Major Healthcare Conference? - StockTitan
Grace Therapeutics reports positive Phase 3 trial results for GTx-104 - MSN
GRCE: STRIVE-ON Results Reported - MSN
Corcept Therapeutics stock soars to all-time high of $62.34 - MSN
Grace Therapeutics’ (GRCE) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright reiterates buy on Grace Therapeutics stock By Investing.com - Investing.com Australia
H.C. Wainwright reiterates buy on Grace Therapeutics stock - Investing.com India
Promising Potential of Grace Therapeutics’ GTX-104 Drives Buy Rating - TipRanks
Grace Therapeutics On Track For NDA Submission Of GTx-104 For Aneurysmal Subarachnoid Hemorrhage - Nasdaq
GRACE THERAPEUTICS Earnings Results: $GRCE Reports Quarterly Earnings - Nasdaq
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update - The Manila Times
Grace Therapeutics Reports Positive Phase 3 STRIVE-ON Trial Results for GTx-104 and Secures $30 Million in Financing; NDA Submission Expected by Mid-2025 - Nasdaq
Grace Therapeutics Inc. (GRCE) reports earnings - Quartz
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results - TradingView
Grace Reports Clinical Trial Victory and Major Cash Infusion in Latest Earnings - StockTitan
Grace Therapeutics, Inc. SEC 10-Q Report - TradingView
Grace Therapeutics secures up to $30 million financing By Investing.com - Investing.com Nigeria
Grace Therapeutics secures $15m for GTx-104 pre-commercial development - MSN
Grace therapeutics announces private placement financing of $30 million - MSN
Finanzdaten der Grace Therapeutics Inc-Aktie (GRCE)
Umsatz
Nettogewinn
Free Cashflow
ENV
10.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):